[{"id":"b43a0337-c647-483c-8be0-62d7bcd2f916","acronym":"FRAME-001","url":"https://clinicaltrials.gov/study/NCT04998474","created_at":"2021-08-10T14:52:55.322Z","updated_at":"2024-07-02T16:36:26.715Z","phase":"Phase 2","brief_title":"FRAME-001 Personalized Vaccine in NSCLC","source_id_and_acronym":"NCT04998474 - FRAME-001","lead_sponsor":"Frame Pharmaceuticals B.V.","biomarkers":" CD8 • IFNG • TNFA • CD4 • IL2","pipe":"","alterations":" ","tags":["CD8 • IFNG • TNFA • CD4 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • FRAME-001"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2021-08-10"}]